CLOSE
MENU
Announcement of Presentation on Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 86th Annual Meeting of the Japanese Society of Hematology
Oct 01, 2024
サブ-ナビゲーション
Company
CEO Message
Mission・2030 Vision
Leadership
Directors
Business Model
Brand Origin
Company Profile
Science/Pipleline
Focused Area
Pipeline Overview
CLK Inhibitor CTX-712
MALT1 Inhibitor CTX-177
CDK12 Inhibitor CTX-439
GCN2 Inhibitor CRD-1968099
News
Investor Relations
Management Policies
Financial Information
IR Library
Stock Information
IR Calender
現在位置:
IR News
IR FAQ
Disclaimer
Career
Contact
Contact
Privacy Policy
Term of use
Sitemap
Announcement of Presentation on Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 86th Annual Meeting of the Japanese Society of Hematology
Oct 01, 2024
VIEW IR NEWS
ページの先頭へ
ページの先頭へ
menu
gnavi-box